Isofol Medical AB - Asset Resilience Ratio

Latest as of December 2025: 65.69%

Isofol Medical AB (ISOFOL) has an Asset Resilience Ratio of 65.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Isofol Medical AB's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr85.00 Million

≈ $9.15 Million USD Cash + Short-term Investments

Total Assets

Skr129.40 Million

≈ $13.93 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Isofol Medical AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ISOFOL asset base.

Liquid Assets Composition Over Time

This chart breaks down Isofol Medical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ISOFOL total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr85.00 Million	65.69%
Total Liquid Assets	Skr85.00 Million	65.69%

Asset Resilience Insights

Very High Liquidity: Isofol Medical AB maintains exceptional liquid asset reserves at 65.69% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Isofol Medical AB Industry Peers by Asset Resilience Ratio

Compare Isofol Medical AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Isofol Medical AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Isofol Medical AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	65.69%	Skr85.00 Million ≈ $9.15 Million	Skr129.40 Million ≈ $13.93 Million	-32.01pp
2024-12-31	97.70%	Skr96.16 Million ≈ $10.35 Million	Skr98.42 Million ≈ $10.59 Million	-0.55pp
2023-12-31	98.26%	Skr138.15 Million ≈ $14.87 Million	Skr140.60 Million ≈ $15.13 Million	+8.98pp
2022-12-31	89.28%	Skr190.58 Million ≈ $20.51 Million	Skr213.46 Million ≈ $22.97 Million	-5.26pp
2021-12-31	94.54%	Skr379.45 Million ≈ $40.83 Million	Skr401.36 Million ≈ $43.19 Million	+15.96pp
2020-12-31	78.57%	Skr116.39 Million ≈ $12.53 Million	Skr148.13 Million ≈ $15.94 Million	-8.12pp
2019-12-31	86.70%	Skr126.98 Million ≈ $13.67 Million	Skr146.47 Million ≈ $15.76 Million	-7.88pp
2018-12-31	94.57%	Skr272.90 Million ≈ $29.37 Million	Skr288.55 Million ≈ $31.05 Million	-4.33pp
2017-12-31	98.91%	Skr357.33 Million ≈ $38.45 Million	Skr361.28 Million ≈ $38.88 Million	+15.40pp
2016-12-31	83.50%	Skr19.11 Million ≈ $2.06 Million	Skr22.89 Million ≈ $2.46 Million	--

pp = percentage points

About Isofol Medical AB

ST:ISOFOL Sweden Biotechnology

Market Cap

$22.39 Million

Skr208.02 Million SEK

Market Cap Rank

#24847 Global

#487 in Sweden

Share Price

Skr0.74

Change (1 day)

+1.37%

52-Week Range

Skr0.58 - Skr0.89

All Time High

Skr33.00